Holen Sie sich die Stockscreener-App
1.12
1.75%
-0.02
Schlusskurs vom Vortag:
$1.14
Offen:
$1.16
24-Stunden-Volumen:
436.81K
Relative Volume:
0.64
Marktkapitalisierung:
$142.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.43M
KGV:
-7.1887
EPS:
-0.1558
Netto-Cashflow:
$-12.87M
1W Leistung:
+10.89%
1M Leistung:
+20.24%
6M Leistung:
-10.40%
1J Leistung:
-44.00%
1-Tages-Spanne:
$1.10
$1.20
1-Wochen-Bereich:
$0.9417
$1.20
52-Wochen-Spanne:
$0.7615
$2.33
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Firmenname
Tiziana Life Sciences Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare TLSA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.12 | 128.53M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2018-12-17 | Eingeleitet | Laidlaw | Buy |
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Market movers: HPE, Boeing, Salesforce, Tiziana Life Sciences... - Proactive financial news
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy - Yahoo Finance
Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy - TipRanks
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) - The Manila Times
Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com Canada
Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial - Proactive financial news
Small cap wrap: M2i Global, Sigma Lithium, 1911 Gold, Tiziana Life Sciences... - Proactive financial news
Tiziana begins dosing ALS patients in Phase 2a trial of nasal antibody foralumab - Pluang
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab - The Manila Times
Three people with ALS have received their first doses in a trial of a nasal drug. - Stock Titan
The ALS Association co-funds a nasal-treatment trial as Tiziana (TLSA) doses its first patients. - Stock Titan
Tiziana doses first three patients in ALS trial of nasal antibody foralumab - Proactive financial news
TLSA Reiterated by BTIG -- Price Target Maintained at $7.00 - GuruFocus
BTIG Maintains Tiziana Life Sciences(TLSA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Small cap wrap: Tiziana Life Sciences, First Phosphate, Ocean Power Technologies, Midnight Sun Mining... - Proactive financial news
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial - Yahoo Finance
Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October - marketscreener.com
Tiziana Life Sciences (TLSA) Completes Phase 2a Trial, Faces Val - GuruFocus
Tiziana Life Sciences Completes Last Patient Visit in Phase 2a INFORM-MS Trial - TipRanks
Tiziana Life Sciences announces last patient completed Phase 2a INFORM-MS trial - TipRanks
Tiziana Life Sciences Announces Last Patient Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis - Quiver Quantitative
The last patient has finished an MS drug trial. Early results are expected in October. - Stock Titan
Last patient finishes Tiziana (TLSA) MS trial ahead of October data - Stock Titan
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Ltd(NasdaqCM: TLSA) dropped from S&P Global BMI Index - marketscreener.com
Tiziana Life Sciences stock jumps on MS trial partnership - Investing.com
Tiziana (TLSA) Up +25.96% — Will the Rally Hold Through Earnings? 2026-09-17Combination Correction - siam.in
Why Is Tiziana Life Sciences Stock Gaining Thursday? - Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Enters MOU to Launch RRMS Combination Therapy Trial - kalkinemedia.com
Small cap wrap: Sigma Lithium, Tiziana Life Sciences, Gunnison Copper, Purepoint Uranium... - Proactive financial news
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial - Yahoo Finance
Tiziana Life Sciences stock jumps on MS trial partnership By Investing.com - Investing.com Canada
Tiziana Life Sciences Signs Saudi Collaboration MOU for New Multiple Sclerosis Trial - TipRanks
Tiziana Life Sciences (TLSA) Advances MS Clinical Trial Collaboration Amid Challenging Valuation - GuruFocus
Tiziana Life Sciences signs MOU with KAIMRC in Saudi Arabia - TipRanks
Tiziana Life Sciences Signs MOU with KAIMRC and Foundation for Neurologic Diseases to Study Intranasal Foralumab in RRMS - Quiver Quantitative
Tiziana (TLSA) lines up MS trial for patients failing current drugs with a nasal antibody twist. - Stock Titan
Tiziana Life Sciences Announces Signing of Mo - Moomoo
A planned MS trial will test Tiziana’s nasal drug with existing treatment - Stock Titan
TLSA: Tiziana Life Sciences Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
BTIG Initiates Tiziana Life Sciences(TLSA.US) With Buy Rating, Announces Target Price $7 - Moomoo
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Yahoo Finance
Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news
Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - GuruFocus
BTIG Initiates Tiziana Life Sciences at Buy With $7 Price Target - marketscreener.com
BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com India
Wall Street ends on a mixed note as Dow gains despite semiconductor slump - proactiveinvestors.com.au
Market movers: Strategy, Bitmine, Tiziana Life Sciences... - Proactive Investors
Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data - Stock Titan
Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tiziana Life Sciences Ltd-Aktie (TLSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Elrifi Ivor | Chief Executive Officer |
Aug 04 '26 |
Buy |
0.97 |
83,807 |
81,293 |
4,556,068 |
| Elrifi Ivor | Chief Executive Officer |
Aug 03 '26 |
Buy |
1.00 |
667,000 |
667,000 |
4,472,261 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):